career at the International Institute for Asian Studies in the Netherlands. In Asia, it examines general challenges of applied science: in conversation (i.e., based on interviews) with the scientists and the patients there, introducing also the providers of treatments and collectors of data, and sketching economies of pharmaceutical industries and insurance. Instead of so-called non-Western, traditional, or even exotic cultural practices, the authors examine universally applicable instruments of genetic testing that produce results about any human being, no matter what they believe or how they are feeling. Instead of essentialist features of the separate nation-states, this volume examines particularities based on the roles of different actors in health care. In the context of decision-making processes about PGT testing and the related treatments in the four Asian countries, the authors of eleven chapters introduce those rather different involved actors respectively. Due to the spectrum of topics, the contributors are a rather diverse group. For example, Gerard Porter in his chapter entitled "Genetic Tests and Insurance in Japan: The Case for a Regulatory Framework" discusses the role of health insurance in Japan, that is, claims for coverage within the framework of compulsory national insurance and still-deficient regulations (145 -66). Ole Döring's chapter focuses on families in China coping with the ominous results of . Helen Wallace's chapter argues that promised dietary applications are taken into question as overly commerce-oriented (201 -10). Sites of discrimination in the four countries demonstrate the problem of sex selection. The index covers sixteen pages and provides a useful overview of key terms, of specific diseases and social groups that are discussed as cases, and of the focus shared by all the authors of very heterogeneous disciplinary backgrounds.
As the authors show, the "ramifications" limiting choices reveal common "themes." Readers can trace them across the chapters and thus across national demarcations and the prevalent negative images of the three developing countries and the one wealthy welfare country, Japan . "Frameworks" of terms and interpretation, experience and behavior are much more than just individual will on the free market of options and opinions in politics. This approach opens up lines of comparison other than those sticking to the modernization and challenge-andresponse paradigms. While the volume does take readers into the different histories of public health and cultural particularities of "choice" in the four countries, the themes confronted in all those cases are similar, and some of the general findings about cultural struggles with the risks and hopes are even the same. In her introductory and concluding chapters the editor lines out central themes running through the volume. Will of the involved actors is intrinsically determined and limited in several ways. Practically, just "free" will does not automatically lead to actual treatments. Ethnographic approaches, that is, social scientific fieldwork, provide access to the actors' responses to conditions of the often very wide ("therapeutic") gap between science and applications. Both in the fields of the state and in markets, the findings of scientists are employed selectively and are thus changing health care campaigns and funding. Discrimination occurs as a result of genetic findings in cultural contexts, from individual nuclear families to the politics of insurance coverage, while nevertheless decisions and debates are determined and limited on globalized scales.
Thus treatments informed by PGT are not restricted to the predominant understanding as healing an individual patient; instead, they often include "free, individual, communal, conditional choices" (221), that is, decisions about options that are heavily loaded with specific cultural meaning, especially about death and killing. Furthermore, how actors imagine their own choices is rather different from how they actually experience them, let alone from how they behave. In the West, just as in Asia, patients rarely express their will individually or even entirely freely. Especially, some religious communities express strong concerns about killing and discharging the cell cluster in a woman's womb, even if it is expected to become a very diseased fetus or to be born as an already miserably dying patient. Bob Simpson's research indicates that this is a major concern prevalent in Sri Lanka (27 -42). On the contrary, Japan still struggles with skepticism against bringing up a disabled child. This echoes haunting ideas of euthanasia from its fascist past. Furthermore, Azumi Tsuge's chapter, entitled "How Japanese Women Describe Their Experiences of Prenatal Testing," and Masae Kato's chapter, "Cultural Notions of Disability in Japan: Their Influence on Prenatal Testing," demonstrate how pregnant women actually deal with the political past and cultural-historical context in Japan today (109 -24 and 125-44, respectively). Furthermore, in the words of Sleeboom-Faulkner elsewhere, "revival and development of traditional religions and beliefs have complicated the discussion about the meaning of the Chinese family" (2011: 1802). In the chapter coauthored with Suli Sui she reconstructs how families in China deal with Duchenne muscular dystrophy and as one of their "desperate actions" (226) resort to treatments with Chinese medicine. Religion and astrology have similar functions in Sri Lanka and India.
Put in social context, data collection confronts practicalities of compliance and financial costs. Screening tackles the forces of profit maximizing behind pharmaceutical sciences. Practicalities of such data collection in the different national environments are examined, for instance, in three chapters about India: choices under the conditions of encounters between rural and tribal Indians and population screening (Prasanna Kumar Patra and Sleeboom-Faulkner, 65 -90), counselors confronting questions of international standards that do not translate directly into ethics of their day-to-day work (Renu Saxena et al., 91-108), and not only public but also private problems of eugenics (Jyotsna Agnihotri Gupta, 43 -64).
As a consequence of political decisions about the allocation of treatments, their unavailability frequently causes a "therapeutic gap" when treatments or tests that could be carried out are not funded or distributed. Furthermore, a budget is needed for testing and data collection, that is, "screening" campaigns and "testing" policies. For the purposes of individual treatment, on the one hand, and of reconstructing the recent past of diseased populations on epistemological maps, on the other, tests nowadays allow scientists to provide diagnoses of a growing number of genetic diseases and even multiple factors. Moreover, PGT also offers some tools to move one step further and estimate future illnesses. Still, neither free scientific research on basic theory nor screening campaigns translate directly into massive improvements of drugs available widely on markets, at least not for the broader population in the near future. This raises the question of how, in society at large, budget shall be allocated. Such data help identify regional backgrounds of particular diseases, as they might otherwise, in the common unspecialized hospital, be unknown to physicians. Furthermore, how shall rights to information be dealt with when insurances restrict treatments to citizens depending on the tests? Citizens resist giving out their data, or the data may concern particular family relations such as sperm donors, or distant relatives that live far apart but are nevertheless decisive for the genetic transmission of illnesses.
Several options arise from one prediction such as an estimated future diagnosis. Another prediction might be probable as well but is not tested. As this volume illustrates by a number of cases, not just patients themselves, especially at a stage when they are yet unborn or in the stage of just some cells, but rather family members and decision makers in government and insurance have to handle those options.
Genetics and the proclaimed "new era" of pharmagenomics have been critically examined by anthropologists (Atkinson, Glaser, and Lock 2009; Strathern 2005) , and are examined in this volume (in the chapter by Sandra Soo-Jin Lee, entitled "The Asian Genome: Racing in an Age of Pharmacogenomics," 211 -22). Consequently, authors on STS in Asia have widely published on general questions: about how to deal with the predicted risks and about how to promise hope and actually distribute relief of the expected hardships to the diseased patients themselves and to their social environment. Among all the involved actors, who shall make decisions about how to comply with the process of testing and whether or not to comply with the proposed clinical intervention?
